C51/A7401/Cancer Research UK/United Kingdom[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2012	1
2015	1
2018	1
2024	0

Page 1

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Lorente D, Mateo J, Zafeiriou Z, Smith AD, Sandhu S, Ferraldeschi R, de Bono JS. Lorente D, et al. Nat Rev Urol. 2015 Jan;12(1):37-47. doi: 10.1038/nrurol.2014.345. Nat Rev Urol. 2015. PMID: 25563847 Review.

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Ang JE, Kaye S, Banerji U. Ang JE, et al. Curr Drug Targets. 2012 Nov;13(12):1525-34. doi: 10.2174/138945012803530062. Curr Drug Targets. 2012. PMID: 22974395 Free PMC article. Review.

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.

Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Scher HI, Terstappen LWMM, de Bono JS. Lorente D, et al. Ann Oncol. 2018 Jul 1;29(7):1554-1560. doi: 10.1093/annonc/mdy172. Ann Oncol. 2018. PMID: 29741566 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year